Blin O, Azulay J P, Desnuelle C, Billé-Turc F, Braguer D, Besse D, Branger E, Crevat A, Serratrice G, Pouget J Y
Department of Medical Pharmacology, Timone University Hospital, Marseille, France.
Clin Neuropharmacol. 1996 Apr;19(2):189-92. doi: 10.1097/00002826-199619020-00009.
In a one-year parallel group double-blind placebo-controlled study of dextromethorphan (1.5 mg/kg) in amyotrophic lateral sclerosis, no significant differences were observed in the rate of progression (Norris scale) in comparing 24 patients randomly assigned to the dextromethorphan group and 25 patients randomly assigned to the placebo group. Of the 24 patients in the dextromethorphan group, 17 had limb onset and 7 had bulbar onset disease; average duration of disease was 12.5 +/- 6 months and sex ratio (M:F) was 1.4:1. Of the 25 patients in the placebo group, 18 had limb onset and 7 had bulbar onset disease; average duration of disease was 9.9 +/- 6 months and sex ratio (M:F) was 1.55:1. Dextromethorphan is a weak noncompetitive N-methyl-D-aspartate (NMDA) antagonist and higher doses or other potent NMDA receptor antagonists should be tested.
在一项为期一年的双盲安慰剂对照平行组研究中，对肌萎缩侧索硬化患者使用右美沙芬（1.5毫克/千克），将24例随机分配至右美沙芬组的患者与25例随机分配至安慰剂组的患者进行比较，未观察到疾病进展速率（诺里斯量表）有显著差异。右美沙芬组的24例患者中，17例为肢体起病型，7例为延髓起病型；疾病平均病程为12.5±6个月，性别比（男：女）为1.4：1。安慰剂组的25例患者中，18例为肢体起病型，7例为延髓起病型；疾病平均病程为9.9±6个月，性别比（男：女）为1.55：1。右美沙芬是一种弱的非竞争性N-甲基-D-天冬氨酸（NMDA）拮抗剂，应测试更高剂量或其他强效NMDA受体拮抗剂。
